Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
N4 Pharma reports progress in Nuvec clinical research
(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday. The AIM-traded firm said that in collaboration with the University of Brunel, it conducted a series of in vitro experiments which yielded promising results.
It said the experiments demonstrated that Nuvec could substantially improve transduction efficacy when combined with adeno-associated virus 8 (AAV8), building on previous work where Nuvec enhanced the transduction efficacy of a standard adenovirus vector.
In particular, the study involved mixing Nuvec with AAV8 carrying a fluorescent green protein gene and using it for transduction in human-like liver cells, modelled after induced pluripotent cells.
The transduction efficacy increased by 2.5 times compared to using the AAV8 vector in isolation.
N4 said AAV8 was chosen for the investigation due to its current use in clinical development projects.
"The number of approvals of new gene therapies and the need for appropriate delivery systems have reached unprecedented highs and demand is growing exponentially," said chief executive officer Nigel Theobald.
"The AAV vector market alone is projected to grow from $1.9bn in 2022 to $11.1bn by 2035, a compound annual growth rate of 14%.
"For in vivo gene therapy, the adenovirus (AV) and adeno-associated virus (AAV) are acknowledged as the most used delivery vehicles."
However, Theobald said relatively high amounts of AV and AAV were needed to be clinically efficient, which appeared directly correlated with adverse patient events such as unwanted immunogenicity and potential safety implications.
"Our work shows that Nuvec has the potential to reduce the amount of AV and AAV needed and thus decrease both the cost of goods and immunogenicity associated with using these viral vectors.
"We believe this will be a major focus of the pharma biotech industry as these viral vector delivery systems are further investigated.
"This work is running in parallel to our ongoing oral and dual loading work as well as the Nanogenics' Glaucoma product, an update on which will follow soon."
At 1040 GMT, shares in N4 Pharma were down 6.15% at 1.22p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.